Conference item icon

Conference item

MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

Abstract:

RAS activating mutations occur in ∼55% of metastatic (m) CRC. RASMT and >50% of RASWT mCRC patients (pts) do not benefit from anti-EGFR antibodies. c-MET is overexpressed in ∼50-60%, amplified in ∼2-3% and mutated in ∼1-3% of mCRC. Preclinical data support the clinical evaluation of MEK1/2 and METi, in particular in RASMT tumours and RASWT with aberrant c-MET expression. The primary aim of the phase I study was to establish the maximum tolerated dose (MTD) and assess safety/toxicity profil...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/annonc/mdw370.28

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
ORCID:
0000-0003-0167-1685
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
More from this funder
Name:
European Research Council
Grant:
FP7 Grant
Publisher:
Oxford University Press
Host title:
Annals of Oncology
Journal:
Annals of Oncology More from this journal
Volume:
27
Issue:
S_6
Pages:
vi149–vi206:480P
Publication date:
2016-10-11
Acceptance date:
2016-05-11
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
Pubs id:
pubs:718811
UUID:
uuid:69c36bba-1ddd-49d0-9b17-e1c82d7e1e43
Local pid:
pubs:718811
Source identifiers:
718811
Deposit date:
2018-01-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP